What Is NIPT and Should I Have It? A Guide for London Mums
What Is NIPT and Should I Have It? A Guide for London Mums
Published
Tags
Non-invasive prenatal testing (NIPT) has revolutionised prenatal screening since its introduction to the UK in 2012, offering expectant mothers a safe and highly accurate way to screen for chromosomal conditions. With the NHS now incorporating NIPT into its screening programme for high-risk pregnancies, many London mums are asking themselves whether this advanced genetic test is right for them. Understanding what NIPT involves and its benefits can help you make an informed decision about your prenatal care.
What Is NIPT?
Non-invasive prenatal testing (NIPT), also known as cell-free DNA screening, is a blood test that analyses fragments of fetal DNA circulating in the mother’s bloodstream. This cutting-edge technology can detect chromosomal abnormalities such as Down’s syndrome (trisomy 21), Edwards’ syndrome (trisomy 18), and Patau’s syndrome (trisomy 13) with remarkable accuracy.
Unlike traditional screening methods that combine blood tests with ultrasound measurements, NIPT screening analyses actual genetic material from the developing baby. This makes it significantly more accurate than conventional screening tests, with detection rates exceeding 99% for Down’s syndrome.
The test is completely safe for both mother and baby, requiring only a simple blood draw from the mother’s arm. There’s no risk of miscarriage, unlike invasive diagnostic tests such as amniocentesis or chorionic villus sampling (CVS).
How Does NIPT Work?
During pregnancy, small fragments of DNA from the placenta circulate freely in the mother’s bloodstream. Since the placenta and baby share the same genetic makeup in the vast majority of cases, this cell-free DNA provides a window into the baby’s chromosomal composition.
The blood sample is sent to a specialised laboratory where sophisticated technology extracts and analyses this fetal DNA. The laboratory examines the chromosomes for any numerical abnormalities that could indicate conditions such as trisomy 21, 18, or 13.
Advanced NIPT tests can also screen for sex chromosome abnormalities, microdeletions, and even determine the baby’s sex. Some comprehensive screening options, such as those offered through genetic testing services, can analyse hundreds of genetic conditions.
When Can NIPT Be Performed?
NIPT can be performed from as early as 9-10 weeks of pregnancy, making it one of the earliest screening options available. This timing allows sufficient fetal DNA to be present in the mother’s bloodstream for accurate analysis.
The early timing of NIPT offers several advantages:
- Early reassurance: Results are typically available within 7-10 working days, providing peace of mind early in pregnancy
- More time for decisions: If further testing is needed, there’s more time to consider options
- Reduced anxiety: Early screening can alleviate concerns throughout the pregnancy
Unlike some traditional screening tests that must be performed within specific time windows, NIPT can be carried out at any point from 10 weeks onwards, offering flexibility for expectant mothers.
Who Should Consider NIPT?
While NIPT is suitable for most pregnancies, certain factors may make it particularly beneficial:
- Maternal age: Women aged 35 and over have an increased risk of chromosomal abnormalities
- Family history: Previous pregnancies affected by chromosomal conditions
- Abnormal ultrasound findings: Structural abnormalities detected during routine scans
- High-risk screening results: Elevated risk from combined or quadruple screening tests
- IVF pregnancies: Some couples undergoing fertility treatment prefer comprehensive screening
- Personal choice: Any pregnant woman seeking maximum reassurance about chromosomal health
The NHS now offers NIPT to women with higher-chance results from initial screening, but many expectant mothers in London choose private NIPT testing for the convenience and comprehensive options available.
Understanding NIPT Results
NIPT results are reported as either ‘low risk’ or ‘high risk’ for each condition tested. It’s crucial to understand that NIPT is a screening test, not a diagnostic test, meaning it indicates probability rather than providing a definitive diagnosis.
A low-risk result provides significant reassurance, with the chance of the condition being present reduced to less than 1 in 10,000 in most cases. However, a high-risk result doesn’t mean the baby definitely has the condition – it indicates an increased likelihood that requires further investigation through diagnostic testing.
Understanding these statistics can be complex, which is why interpreting NIPT statistics often benefits from professional genetic counselling. The positive predictive value of NIPT varies depending on maternal age, the specific condition, and individual risk factors.
Types of NIPT Available
Several NIPT options are available, ranging from basic screening to comprehensive genetic analysis:
- Basic NIPT: Screens for trisomy 21, 18, and 13, plus sex chromosome abnormalities
- Extended NIPT: Includes additional chromosomal conditions and microdeletion syndromes
- Comprehensive NIPT: Advanced testing covering hundreds of genetic conditions
- Specific tests: Such as PrenatalSafe NIPT or Unity NIPT, each with different coverage levels
The choice between different NIPT types depends on individual preferences, risk factors, and the level of screening coverage desired. More comprehensive tests provide broader screening but come with higher costs and potentially more complex results interpretation.
NIPT vs Traditional Screening
Traditional first-trimester screening combines blood tests measuring pregnancy hormones with ultrasound measurements of nuchal translucency. While this approach has been the standard for years, NIPT offers several advantages:
- Higher accuracy: Detection rates above 99% for Down’s syndrome compared to 85-95% for combined screening
- Lower false positive rates: NIPT has false positive rates below 1% compared to 5% for traditional screening
- No ultrasound dependency: Results don’t rely on scan measurements, which can be operator-dependent
- Single test: Only requires a blood draw rather than coordinating blood tests and scans
However, traditional screening remains valuable as it includes ultrasound assessment of fetal development and can detect structural abnormalities that NIPT cannot identify. Many women opt for both approaches to maximise detection rates.
Limitations of NIPT
While NIPT is highly accurate, it’s important to understand its limitations:
- Screening not diagnostic: Results indicate risk levels, not definitive diagnoses
- Limited scope: Cannot detect neural tube defects, structural abnormalities, or all genetic conditions
- Test failures: Approximately 1-5% of tests may fail due to insufficient fetal DNA
- Placental mosaicism: Rare cases where placental DNA doesn’t match fetal DNA
- Twin pregnancies: Accuracy may be reduced in multiple pregnancies
These limitations highlight why NIPT works best as part of comprehensive prenatal care, often combined with detailed ultrasound scanning and professional genetic counselling when needed.
Considering the Costs
The NHS provides NIPT free of charge for women with higher-chance screening results, but many expectant mothers choose private testing for immediate access and comprehensive options. Private NIPT costs in London vary depending on the test comprehensiveness and clinic chosen.
When considering costs, factor in:
- Test comprehensiveness: More extensive screening panels cost more but provide broader coverage
- Turnaround time: Express services may carry premium pricing
- Genetic counselling: Professional guidance may be included or available as an additional service
- Follow-up care: Consider whether additional support is included if results require further investigation
Many couples view NIPT as an investment in peace of mind during pregnancy, with the reassurance often outweighing the financial consideration.
Making Your Decision
Deciding whether to have NIPT is deeply personal and depends on various factors unique to your situation. Consider these questions when making your choice:
- What level of reassurance do you need? NIPT provides highly accurate screening that can offer significant peace of mind
- How would you use the information? Consider how results might influence your pregnancy journey and decisions
- What are your risk factors? Age, family history, and previous pregnancies may influence the benefits
- Can you handle uncertainty? Remember that screening provides risk assessment, not definitive answers
There’s no right or wrong choice – some women prefer comprehensive screening while others are comfortable with routine NHS care. Modern prenatal screening offers options to suit different preferences and circumstances.
How the London Pregnancy Clinic Can Help
At London Pregnancy Clinic, we offer comprehensive NIPT services with the expertise and support you need to make informed decisions about prenatal screening. Our specialist team provides various screening options, from basic chromosomal screening to advanced genetic analysis covering hundreds of conditions.
Our services include:
- Multiple NIPT options: Choose from various test types to match your screening preferences and requirements
- Expert genetic counselling: Professional guidance to help understand results and implications
- Combined scan packages: NIPT can be combined with detailed ultrasound examinations for comprehensive assessment
- Rapid results: Quick turnaround times to minimise anxiety during the waiting period
- Follow-up support: Continued guidance if results require further investigation or consultation
Our experienced team understands the importance of choosing the right NIPT provider and ensures you receive personalised care throughout your screening journey.
Final Thoughts
NIPT represents a significant advancement in prenatal care, offering expectant mothers highly accurate, safe screening for important chromosomal conditions. While the decision to undergo testing is personal, understanding what NIPT involves and its benefits can help you make the choice that’s right for your family.
Whether you’re seeking basic reassurance about the most common chromosomal conditions or comprehensive screening for hundreds of genetic disorders, NIPT provides valuable information that can enhance your pregnancy journey. The key is choosing the right test and provider to meet your individual needs and circumstances.
If you’re considering NIPT screening, speaking with experienced professionals can help clarify your options and ensure you make an informed decision that provides the reassurance and information you’re seeking during this important time.
Sources
- Non Invasive Prenatal Testing in London – Pregnancy DNA Test
- Non-Invasive Prenatal Testing (NIPT) – The SAFE Test – St George’s University Hospitals NHS Foundation Trust
- SMART Test NIPT Test at the London Pregnancy Clinic
- Non-Invasive Prenatal Testing (NIPT) – Antenatal Results and Choices (ARC)
- What is NIPT? – Genomics Education Programme
- New operational guidance for NIPT screening within the NHS – PHE Screening
- Non-invasive prenatal testing (NIPT) | Imperial College Healthcare Private Care
- Non-invasive prenatal testing (NIPT) — Knowledge Hub
- Presentation: Patient with a higher-chance non-invasive prenatal test (NIPT) result — In the Clinic
- KNOVA NIPT Test London | UK Pioneers in Advanced Screening
- NIPT PPV Calculator – London Pregnancy Clinic
- Non-Invasive Prenatal Testing (NIPT) in London | CRGH
Latest Stories
What is SMA and Why is it Trending Right Now?
What is SMA and Why is it Trending Right Now?
Published
Tags
Spinal muscular atrophy (SMA) has become increasingly prominent in medical discussions, particularly as around 70 children are born with this rare genetic condition each year in the UK. This neuromuscular disorder is trending not only because of breakthrough treatments but also due to enhanced carrier screening tests that can help prospective parents understand their risks. Understanding SMA is crucial for couples planning a family, as early detection and intervention can significantly impact outcomes.
Understanding Spinal Muscular Atrophy
Spinal muscular atrophy is a genetic neuromuscular disorder that causes certain muscles to become weak and waste away. This condition affects the motor neurones in the spinal cord, which are responsible for controlling voluntary muscle movement. When these nerve cells deteriorate, muscles cannot receive the signals they need to function properly, leading to progressive weakness and atrophy.
SMA is caused by mutations in the SMN1 gene, which produces a protein essential for motor neurone survival. Without sufficient levels of this protein, motor neurones gradually die, resulting in muscle weakness that typically affects the muscles closest to the centre of the body first, including those controlling breathing, swallowing, and movement.
The condition follows an autosomal recessive inheritance pattern, meaning both parents must carry a faulty copy of the gene for their child to develop SMA. Our comprehensive spinal muscular atrophy information provides detailed guidance for families considering genetic screening.
The Five Types of SMA
SMA is classified into five distinct types based on the age of onset and severity of symptoms. Understanding these classifications helps healthcare professionals and families plan appropriate care and set realistic expectations.
- SMA Type 0: The most severe form, with symptoms appearing before birth. Babies are born with severe muscle weakness and breathing difficulties.
- SMA Type 1 (Werdnig-Hoffmann disease): Symptoms appear within the first six months of life. Children typically cannot sit without support and face significant breathing and feeding challenges.
- SMA Type 2: Onset occurs between 6-18 months. Children can sit independently but cannot walk unassisted. Most maintain this ability throughout childhood.
- SMA Type 3 (Kugelberg-Welander disease): Symptoms begin after 18 months of age. Children can walk independently initially but may lose this ability over time.
- SMA Type 4: Adult-onset form with mild symptoms that typically don’t affect life expectancy significantly.
The NHS recognises that early diagnosis is crucial, as new treatments are most effective when started as soon as possible after birth.
Why SMA is Trending in Medical Circles
Several factors have brought SMA to the forefront of medical and public attention in recent years. The development of groundbreaking treatments has transformed what was once considered an untreatable condition into one where early intervention can dramatically improve outcomes.
The introduction of gene therapies and other disease-modifying treatments on the NHS has created renewed hope for families affected by SMA. These treatments work best when administered early, making prenatal and newborn screening increasingly important. The success stories emerging from early treatment programmes have captured media attention and raised public awareness.
Additionally, advances in genetic screening technology have made it easier and more accessible for couples to understand their carrier status. Advanced prenatal screening can now detect SMA risk with greater accuracy than ever before, leading to increased uptake of testing services.
High-profile campaigns by patient advocacy groups and increased research funding have also contributed to SMA’s visibility. The condition has gained attention from celebrities and public figures, further raising awareness about this previously little-known genetic disorder.
Carrier Screening and Inheritance Patterns
Approximately one in 40-50 people in the UK carries a faulty copy of the SMN1 gene, making SMA carrier screening particularly relevant for prospective parents. When both parents are carriers, there is a 25% chance with each pregnancy that their child will have SMA, a 50% chance the child will be a carrier, and a 25% chance the child will be unaffected.
Carrier screening can be performed before conception or during early pregnancy. The test involves a simple blood sample that analyses DNA for mutations in the SMN1 gene. Most carriers have no symptoms and are unaware of their status until testing reveals it.
If both partners are identified as carriers, genetic counselling becomes essential. Our genetic counselling services help couples understand their options, which may include prenatal diagnostic testing, preimplantation genetic testing (PGT), or accepting the natural risk.
The Human Fertilisation and Embryology Authority (HFEA) has approved the use of PGT-M for couples at risk of having a child with SMA Types 1, 2, or 3, providing options for family planning before pregnancy occurs.
Symptoms and Early Warning Signs
Recognising the early signs of SMA is crucial for timely intervention. Symptoms vary depending on the type of SMA, but certain warning signs should prompt immediate medical attention.
- Muscle weakness: Progressive weakness that typically affects muscles closest to the torso first, including shoulders, hips, and back.
- Delayed motor milestones: Late achievement of sitting, standing, or walking compared to typical developmental timelines.
- Breathing difficulties: Weak respiratory muscles can cause breathing problems, particularly during sleep or illness.
- Feeding challenges: Difficulty sucking, swallowing, or maintaining adequate nutrition due to weak facial and throat muscles.
- Tremor: Fine trembling of fingers and hands, particularly noticeable when arms are extended.
- Reduced fetal movement: In severe cases, decreased movement may be noticed during pregnancy.
Parents who notice these symptoms should seek immediate medical evaluation. Early diagnosis allows for prompt treatment initiation, which can significantly improve outcomes and quality of life.
Diagnostic Methods and Testing
Diagnosing SMA involves several approaches, depending on when the condition is suspected. Prenatal diagnosis is possible when both parents are known carriers, whilst postnatal diagnosis typically follows clinical suspicion based on symptoms.
Genetic testing remains the gold standard for SMA diagnosis. A blood sample can reveal deletions or mutations in the SMN1 gene that cause the condition. This testing can be performed prenatally through chorionic villus sampling (CVS) or amniocentesis if both parents are carriers.
Additional diagnostic tools may include electromyography (EMG) to assess muscle and nerve function, muscle biopsy in certain cases, and creatine kinase blood tests. However, genetic testing has largely replaced these more invasive procedures.
The UK National Screening Committee continues to evaluate the potential for newborn screening for SMA, recognising that early detection could improve treatment outcomes. Some regions have begun pilot programmes to assess the feasibility and benefits of population-wide newborn screening.
Treatment Breakthroughs and NHS Availability
The treatment landscape for SMA has been revolutionised in recent years, transforming the outlook for affected children and their families. Three main disease-modifying treatments are now available through the NHS, each working through different mechanisms to address the underlying genetic cause.
Spinraza (nusinersen) was the first approved treatment, administered through spinal injections every four months. This antisense oligonucleotide helps increase production of functional SMN protein from the backup SMN2 gene.
Zolgensma represents a breakthrough in gene therapy, providing a functional copy of the SMN1 gene through a single intravenous infusion. This treatment is most effective when given to babies before symptoms develop or in very early stages of the disease.
Evrysdi (risdiplam) offers an oral treatment option, taken daily as a liquid medicine. This small molecule drug increases SMN protein production and can be used across all SMA types and ages.
The NHS has made these treatments available following NICE approval, recognising their potential to dramatically improve outcomes when started early. Success stories include children who have achieved motor milestones previously thought impossible for their SMA type.
Impact on Family Planning Decisions
The availability of effective treatments has significantly influenced how families approach SMA risk in pregnancy planning. Where previously a positive diagnosis might have led to difficult pregnancy decisions, many families now feel more confident proceeding with pregnancies when SMA is detected.
However, the importance of early detection has never been greater. The most effective outcomes occur when treatment begins before symptoms develop, making prenatal diagnosis and immediate postnatal intervention crucial.
Families with a known risk of SMA have several options to consider. Prepregnancy genetic testing can identify carrier status before conception, allowing couples to make informed decisions about their reproductive choices.
For families who choose to proceed with a pregnancy at risk for SMA, comprehensive prenatal care and planning for immediate postnatal intervention becomes essential. This includes coordination with specialist neuromuscular centres and preparation for early treatment initiation if needed.
The Role of Genetic Counselling
Genetic counselling plays a vital role in helping families navigate SMA-related decisions. Professional genetic counsellors provide essential support in understanding inheritance patterns, risk assessment, and available options for testing and family planning.
During counselling sessions, families learn about the implications of carrier status, the likelihood of having an affected child, and the various testing options available. Counsellors also provide emotional support and help families process complex medical information.
For families with an SMA diagnosis, genetic counselling extends to discussing treatment options, coordinating care with specialist centres, and planning for future pregnancies. The recurrence risk remains 25% for subsequent pregnancies, making ongoing genetic counselling valuable.
Our genetic testing and counselling services provide comprehensive support throughout this process, ensuring families have access to accurate information and emotional support when making these important decisions.
Latest Research and Future Developments
Research into SMA continues to advance rapidly, with several promising developments on the horizon. Scientists are investigating combination therapies that might provide even greater benefits than current single treatments.
Studies are exploring the potential for prenatal treatment, where therapy could begin before birth to prevent symptom development entirely. Early research suggests this approach might offer the best possible outcomes for the most severe forms of SMA.
Improved screening methods are also under development, including more comprehensive carrier screening panels and enhanced newborn screening protocols. These advances could identify more at-risk pregnancies and affected newborns, enabling earlier intervention.
Long-term outcome studies are providing valuable data about the effectiveness of current treatments, helping clinicians optimise treatment protocols and timing. This research is particularly important for understanding how early intervention affects long-term development and quality of life.
How the London Pregnancy Clinic Can Help
The London Pregnancy Clinic offers comprehensive genetic screening and counselling services to support families concerned about SMA and other genetic conditions. Our experienced team provides expert guidance throughout the screening and diagnostic process.
We offer advanced carrier screening tests that can identify SMA carrier status in prospective parents. Our clinical genetics consultations provide detailed risk assessment and counselling for couples considering their family planning options.
For pregnancies identified as being at risk for SMA, we provide specialised prenatal diagnostic services and coordinate care with leading fetal medicine specialists. Our genetic counselling sessions ensure families receive comprehensive support and information to make informed decisions.
We also offer advanced prenatal screening through NIPT and other genetic testing options, helping identify pregnancies that may benefit from further diagnostic testing. Our state-of-the-art facilities and expert sonographers provide detailed ultrasound assessments when indicated.
Final Thoughts
Spinal muscular atrophy represents both a significant challenge and a remarkable success story in modern genetics and medicine. The transformation from an untreatable condition to one where early intervention can dramatically improve outcomes demonstrates the power of scientific advancement and dedicated research.
For prospective parents, understanding SMA and carrier screening options has never been more important. The availability of effective treatments means that early detection and intervention can make a profound difference in a child’s development and quality of life.
If you’re concerned about genetic conditions like SMA or considering carrier screening, our expert team is here to provide guidance and support. Contact the London Pregnancy Clinic to discuss your options and ensure you have access to the latest screening technologies and genetic counselling services.
Sources
- SMA (Spinal Muscular Atrophy): What It Is, Symptoms & Types
- Carrier Screening for Spinal Muscular Atrophy (SMA) | ACOG
- Presentation: Pregnancy at risk of spinal muscular atrophy — In the Clinic
- Family Planning For Couples Affected By 5q SMA – SMAUK
- Prenatal Management of Spinal Muscular Atrophy in the Era of Genetic Screening and Emerging Opportunities in In Utero Therapy – PMC
- Spinal muscular atrophy (SMA) – NHS
- Spinal muscular atrophy – UK National Screening Committee (UK NSC) – GOV.UK
- NHS England » New NHS treatments helping extend survival for babies with rare muscle-wasting disease
- Spinal muscular atrophy (SMA) | Great Ormond Street Hospital
- Spinal muscular atrophy type 1: NCARDRS report – NDRS
- Spinal muscular atrophy (SMA) – Muscular Dystrophy UK
- Spinal Muscular Atrophy (SMA) | Nemours KidsHealth
Latest Stories
KNOVA NIPT: London Pregnancy Clinic Pioneers Advanced Genetic Screening in the UK
KNOVA NIPT: London Pregnancy Clinic Pioneers Advanced Genetic Screening in the UK
Published
Tags
The London Pregnancy Clinic stands as the pioneering force behind introducing KNOVA NIPT to the United Kingdom, establishing ourselves as the country’s leading authority in this revolutionary genetic screening technology. With hundreds of successful KNOVA NIPT procedures completed, our clinical team possesses unparalleled expertise that no other UK clinic can match, offering expectant parents the most advanced non-invasive prenatal testing available today.
What is KNOVA NIPT?
KNOVA NIPT (Non-Invasive Prenatal Testing) represents the cutting-edge of genetic screening technology, developed by Fulgent Genetics to provide comprehensive chromosomal analysis from a simple maternal blood sample. Unlike traditional screening methods, KNOVA NIPT can detect a wide range of genetic conditions with exceptional accuracy, typically achieving over 99% detection rates for common trisomies including Down syndrome (Trisomy 21), Edwards syndrome (Trisomy 18), and Patau syndrome (Trisomy 13).
This revolutionary test analyses cell-free foetal DNA circulating in the mother’s bloodstream, eliminating the need for invasive procedures such as amniocentesis or chorionic villus sampling. The technology behind KNOVA NIPT utilises advanced sequencing techniques to examine chromosomal abnormalities, microdeletions, and other genetic variations that could impact your baby’s health and development.
What sets KNOVA NIPT apart from other screening options is its comprehensive scope, capable of detecting up to 100 different chromosomal and genetic conditions. This extensive coverage provides expectant parents with detailed insights into their baby’s genetic profile, enabling informed decision-making throughout their pregnancy journey.
London Pregnancy Clinic: The UK’s KNOVA NIPT Pioneers
The London Pregnancy Clinic holds the distinguished position of being the first healthcare provider to introduce KNOVA NIPT to the United Kingdom. Our pioneering status isn’t merely historical; it represents years of dedicated research, clinical validation, and continuous refinement of testing protocols to ensure optimal outcomes for our patients.
Having performed hundreds of KNOVA NIPT procedures, our clinical team has accumulated invaluable expertise that extends far beyond simple test administration. We understand the nuances of patient counselling, the intricacies of result interpretation, and the importance of providing comprehensive support throughout the testing process. This depth of experience enables us to guide expectant parents through every aspect of their genetic screening journey with confidence and compassion.
Our pioneering work with KNOVA NIPT has established protocols and best practices that other clinics across the UK now follow. We continue to collaborate with Fulgent Genetics to advance the technology further, ensuring our patients always receive the most current and comprehensive genetic screening available. This commitment to innovation and excellence has made us the preferred choice for healthcare professionals and expectant parents seeking the highest standard of prenatal genetic testing.
The Science Behind KNOVA NIPT Excellence
KNOVA NIPT employs sophisticated next-generation sequencing (NGS) technology to analyse cell-free foetal DNA with remarkable precision. During pregnancy, small fragments of the baby’s DNA circulate in the mother’s bloodstream, typically comprising 3-13% of the total circulating DNA. Our laboratory partners utilise advanced bioinformatics algorithms to distinguish between maternal and foetal DNA sequences, enabling accurate detection of chromosomal abnormalities.
The test’s exceptional accuracy stems from its ability to analyse millions of DNA fragments simultaneously, creating a comprehensive genetic profile that traditional screening methods cannot achieve. This technological advancement allows KNOVA NIPT to detect not only common trisomies but also rare chromosomal conditions and microdeletions that affect fewer than 1 in 1000 pregnancies.
Our expertise in KNOVA NIPT extends to understanding the technical limitations and optimal timing for testing. We recommend performing the test after 9 weeks of pregnancy when foetal DNA levels are sufficient for accurate analysis. Our experienced phlebotomists ensure proper sample collection and handling, whilst our clinical team provides thorough pre-test counselling to ensure patients understand the scope and limitations of the screening.
Comprehensive Genetic Conditions Detected
KNOVA NIPT’s comprehensive screening capability encompasses a broad spectrum of genetic conditions, making it the most thorough non-invasive prenatal test available in the UK. The test categorises conditions into several key areas, each providing crucial information about your baby’s genetic health.
- Common Trisomies: Down syndrome (Trisomy 21), Edwards syndrome (Trisomy 18), and Patau syndrome (Trisomy 13) with over 99% detection accuracy.
- Sex Chromosome Abnormalities: Turner syndrome, Klinefelter syndrome, Triple X syndrome, and XYY syndrome affecting sexual development and fertility.
- Rare Trisomies: Additional chromosomal duplications including Trisomies 9, 16, and 22 that can impact foetal development.
- Microdeletions: Small chromosomal deletions including 22q11.2 deletion syndrome (DiGeorge syndrome), Prader-Willi syndrome, and Angelman syndrome.
- Copy Number Variants: Chromosomal duplications and deletions that may affect intellectual development and physical characteristics.
Our extensive experience with KNOVA NIPT enables us to provide detailed counselling about each condition, helping parents understand the implications of positive results and the importance of confirmatory testing when necessary.
The KNOVA NIPT Testing Process
Our streamlined KNOVA NIPT process reflects years of refinement based on hundreds of successful procedures. The journey begins with a comprehensive consultation where our specialist team discusses your medical history, family background, and specific concerns about genetic conditions. This personalised approach ensures that KNOVA NIPT is appropriate for your individual circumstances.
The testing procedure itself is remarkably straightforward, requiring only a simple blood draw from the expectant mother. Our experienced phlebotomists ensure comfortable sample collection using specialised tubes designed to preserve cell-free DNA integrity. We combine this blood test with a detailed pregnancy assessment including ultrasound scanning to confirm gestational age and foetal viability.
Sample processing occurs in Fulgent Genetics’ state-of-the-art laboratories, where advanced sequencing technology analyses the genetic material. Results are typically available within 7-10 working days, after which our clinical team schedules a comprehensive results consultation to discuss findings, answer questions, and provide ongoing support as needed.
Clinical Advantages of Our Expertise
Our position as the UK’s KNOVA NIPT pioneers translates into tangible clinical advantages for our patients. Having performed hundreds of these tests, we have developed sophisticated protocols for managing complex cases, including multiple pregnancies, previous pregnancy complications, and patients with specific risk factors that may affect test accuracy.
Our clinical team’s extensive experience enables us to identify cases where KNOVA NIPT may provide inconclusive results, such as maternal mosaicism or confined placental mosaicism. We have established clear pathways for managing these situations, including repeat testing protocols and alternative screening strategies when appropriate.
Furthermore, our expertise extends to post-test management, including coordination with specialist genetic counsellors, foetal medicine specialists, and other healthcare providers when positive results require further investigation. We maintain strong relationships with leading UK genetic centres, ensuring seamless referral pathways for confirmatory testing and ongoing care.
Integration with the SMART Test Programme
KNOVA NIPT forms the cornerstone of our innovative SMART Test programme, which combines advanced genetic screening with detailed ultrasound assessment. This comprehensive approach, developed exclusively at the London Pregnancy Clinic, provides the most thorough evaluation of foetal health available in the UK.
The SMART Test KNOVA package includes two expert foetal scans alongside the genetic screening, creating a dual approach that maximises detection of both genetic and structural abnormalities. Our specialist sonographers perform detailed anatomical surveys whilst the KNOVA NIPT analyses chromosomal integrity, providing complementary information that enhances overall screening accuracy.
This integrated approach reflects our understanding that genetic conditions often have physical manifestations that can be detected through expert ultrasound examination. By combining these modalities, we can provide expectant parents with the most comprehensive assessment of their baby’s health, backed by our unparalleled expertise in both genetic screening and prenatal imaging.
Accuracy and Reliability
KNOVA NIPT demonstrates exceptional accuracy rates that have been validated through our extensive clinical experience. For common trisomies, the test achieves sensitivity rates exceeding 99%, with false positive rates remaining below 0.1%. These performance metrics represent real-world outcomes from our hundreds of completed tests, providing robust evidence of the technology’s clinical reliability.
Our experience has enabled us to identify factors that may influence test reliability such as medical history and genetic conditions. We use this knowledge to optimise testing protocols and provide patients with realistic expectations about test performance in their specific circumstances.
It’s important to understand that KNOVA NIPT is a screening test, not a diagnostic procedure. Positive results require confirmatory testing through amniocentesis or chorionic villus sampling. Our extensive experience includes managing the emotional and clinical aspects of positive results, ensuring patients receive appropriate support and timely access to confirmatory procedures when needed.
Patient Experience and Support
Our pioneering experience with KNOVA NIPT has taught us that technical excellence must be matched with exceptional patient care. We understand that genetic screening can provoke anxiety and uncertainty, which is why we have developed comprehensive support protocols that address both the clinical and emotional aspects of prenatal testing.
From initial consultation through results delivery, our patients benefit from continuous access to specialist support. We provide detailed pre-test counselling that explains the scope of conditions tested, the meaning of results, and the implications for pregnancy management. This educational approach empowers patients to make informed decisions about their genetic screening options.
Our post-test support includes detailed results consultations, access to genetic counselling services, and coordination with other specialists when additional care is required. We maintain long-term relationships with our patients, providing ongoing support throughout pregnancy and beyond when genetic conditions are identified.
Comparing KNOVA NIPT to Other Tests
Our extensive experience with multiple NIPT platforms positions us uniquely to advise patients about the advantages of KNOVA NIPT compared to alternative screening options. Unlike more limited tests that screen for only common trisomies, KNOVA NIPT provides comprehensive analysis of up to 100 genetic conditions, offering unparalleled screening breadth.
Traditional NHS screening programmes, whilst valuable, cannot match the scope and accuracy of KNOVA NIPT. The combined first trimester screening offered through the NHS detects approximately 85% of Down syndrome cases, compared to KNOVA NIPT’s >99% detection rate. Additionally, NHS screening cannot detect the rare genetic conditions and microdeletions that KNOVA NIPT identifies.
When compared to other private NIPT options, KNOVA NIPT’s comprehensive panel and advanced technology provide superior clinical value. Our experience demonstrates that patients increasingly prefer comprehensive screening that can detect rare conditions, particularly when family history or other risk factors suggest increased genetic risk.
How the London Pregnancy Clinic Can Help
As the UK’s pioneering KNOVA NIPT provider, the London Pregnancy Clinic offers unmatched expertise in advanced prenatal genetic screening. Our specialist team combines extensive clinical experience with state-of-the-art technology to provide the most comprehensive genetic assessment available to expectant parents.
We offer flexible appointment scheduling at our modern clinic locations, with same-day results consultations available when needed. Our integrated approach combines KNOVA NIPT with expert ultrasound assessment, providing comprehensive evaluation of both genetic and structural foetal development.
Our commitment to excellence extends beyond testing to include comprehensive patient support, detailed counselling services, and seamless coordination with other specialists when additional care is required. We maintain the highest standards of clinical governance whilst providing the personalised care that makes genetic screening as comfortable and informative as possible.
For expectant parents seeking the most advanced genetic screening available, combined with unparalleled clinical expertise, the London Pregnancy Clinic represents the gold standard in UK prenatal care. Our pioneering work with KNOVA NIPT continues to set new benchmarks for genetic screening excellence.
Final Thoughts
The London Pregnancy Clinic’s pioneering role in introducing KNOVA NIPT to the UK reflects our unwavering commitment to advancing prenatal care through innovative technology and clinical excellence. Our extensive experience with hundreds of successful procedures has established us as the nation’s leading authority in comprehensive genetic screening.
For expectant parents seeking the most advanced genetic screening available, KNOVA NIPT offers unparalleled insight into their baby’s genetic health. Combined with our expert clinical team’s guidance and support, this technology provides the foundation for informed decision-making throughout pregnancy.
If you’re considering genetic screening during pregnancy, we invite you to benefit from our pioneering expertise and comprehensive approach to prenatal care. Contact the London Pregnancy Clinic today to schedule your consultation and discover how our KNOVA NIPT experience can provide you with the confidence and reassurance you deserve during this important time.
Latest Stories
Genetic Counselling Services Launch
Genetic Counselling Services Launch
Discover the importance of Genetic Counselling before and during pregnancy.
-
Published
-
Last Modified
Tags
London Pregnancy Clinic proudly announces the launch of our new genetic counselling services. These services focus on reproductive genetic carrier screening. Our goal is to provide vital information to individuals and couples about their genetic risks. This information helps them make informed reproductive decisions aligned with their values and beliefs.
-
-
We are excited to introduce genetic counselling services at London Pregnancy Clinic. These services aim to help prospective parents understand their genetic risks. Genetic counselling is crucial in modern prenatal care. It offers both pre-test and post-test support, guiding you through complex genetic information.
Additionally, we are delighted to welcome Ms Ailidh Watson, our new genetic counselling specialist, to our team. Ailidh brings a wealth of experience and expertise in genetic counselling, particularly in prenatal care and patients with cleft lip and/or palate.
Genetic Testing We offer
At London Pregnancy Clinic, we offer a range of advanced genetic tests. These tests provide crucial information about your reproductive health. Here are the key tests we provide:
SMART Test: Our SMART Test NIPT is the most advanced non-invasive prenatal test and scan package in the world. This signature test gives parents detailed knowledge about their baby’s health without the risks of invasive testing. We offer two genetic packages: SMART Test KNOVA, performed by the leading US lab Fulgent, and SMART Test Genoma, performed by the top European lab Eurofins. Genetic counselling before the SMART test is essential to understand its advantages and limitations, ensuring you make an informed decision about your baby’s health.
Basic NIPT: The Basic NIPT is another non-invasive prenatal test we offer. It focuses on detecting the most common chromosomal abnormalities, including Down syndrome. Like the NIPT Smart Test, it uses a simple blood draw from the mother. This test is an excellent option for those seeking essential genetic information. With its high accuracy, it ensures peace of mind during pregnancy.
Carrier Screening: Our comprehensive carrier screenings identify if you or your partner are carriers of specific genetic disorders. This test covers a wide range of conditions, including cystic fibrosis and spinal muscular atrophy. Knowing your carrier status helps in planning for a healthy pregnancy. It allows you to explore reproductive options like IVF with preimplantation genetic testing (PGT). Moreover, carrier screening informs family members about potential genetic risks.
It’s important to distinguish between Non-Invasive Prenatal Testing (NIPT) and carrier screening:
- NIPT: Performed during pregnancy, typically between 10-20 weeks. It screens the fetus’s DNA for chromosomal abnormalities like Down syndrome.
- Carrier Screening: Tests the parents’ DNA for specific gene mutations that could be passed to their child. It can be done before or during pregnancy.
Benefits of Genetic Testing
Genetic testing offers several advantages, not just for you but for your entire family. Here are some key benefits:
Understanding Health Risks: Genetic testing identifies if you or your partner carry genes for specific genetic conditions. This understanding helps assess the risk of passing these conditions to your children.
Informed Decisions: Knowing your genetic risks allows you to make informed choices about pregnancy and family planning. You can consider options like IVF with preimplantation genetic testing (PGT-M), early interventions, or other preventive measures.
Personalised Care: With detailed genetic information, doctors can provide more personalised care. They can recommend specific tests, treatments, or lifestyle changes to help manage or reduce health risks.
Family Health Insights: Genetic testing reveals crucial health information that may affect other family members. If a genetic condition is identified, relatives can also get tested and take steps to manage their health.
Early Intervention: Detecting genetic conditions early leads to timely interventions and better management. This approach improves the quality of life for affected individuals.
Peace of Mind: For many, genetic testing provides peace of mind. Knowing your genetic information can alleviate uncertainties about potential health risks.
Preventive Measures: Genetic testing enables preventive measures, potentially reducing the risk of having a child with a genetic syndrome.
Overall, genetic testing empowers you with knowledge about your health and your family’s health. It helps you make well-informed decisions and take proactive steps. This ensures the best possible outcomes for you and your loved ones.
Impact on Family Planning?
Our carrier screening tests identify carriers of specific genetic disorders. Even without symptoms, you might still be a carrier. This knowledge is crucial for informed family planning. Knowing your carrier status can significantly influence family planning decisions. Couples who are both carriers face a 25% risk of having an affected child. This information empowers them to explore various reproductive options, such as:
- Using donor gametes to conceive.
- Pursuing in vitro fertilisation (IVF) with preimplantation genetic testing (PGT).
- Accepting the risk and preparing for a potentially affected child.
- Considering adoption or remaining childless.
Carrier results can also influence the timing of pregnancy, prenatal testing decisions, early intervention for certain conditions, and emotional preparedness. Carrier screening identifies carriers for many genetic conditions, including:
- Cystic Fibrosis
- Spinal Muscular Atrophy (SMA)
- Sickle Cell Disease
- Tay-Sachs Disease
- Fragile X Syndrome
- Duchenne Muscular Dystrophy
Other conditions include Thalassemias (alpha and beta), Familial Dysautonomia, Fanconi Anemia, Gaucher Disease, and Niemann-Pick Disease.
Importance of Genetic counselling
Genetic counselling is vital in the carrier screening process. Our certified clinical genetic counsellors are dedicated to supporting you through every step. Here’s how:
Educating the Public and Healthcare Professionals: We provide standardised education about genetic carrier screening. This knowledge empowers you and your healthcare providers with essential information.
Pre-Test Counselling: Before testing, we outline the screening process and potential outcomes. This preparation ensures you are fully informed and ready.
Post-Test Counselling: After testing, we interpret your results and discuss your options. This support helps you understand your situation and make informed decisions about your reproductive health.
Collaborating with Healthcare Providers: Our counsellors work with other healthcare providers to ensure comprehensive care in complex cases. This collaboration enhances your overall care experience.
In summary, London Pregnancy Clinic’s genetic testing and genetic counselling services offer comprehensive support and essential information. These services empower you to make informed decisions and take proactive steps for your family’s health. For more information or to schedule a test, please visit our website or contact us directly. Our team is here to support you in planning a healthy future for your family.
Ethical and Emotional Support:
Genetic counselling provides ethical guidance and emotional support. Our genetic counsellors help individuals and families navigate complex genetic information. Here’s how we assist:
- Risk Assessment: We evaluate your risk based on family history, ethnic background, and genetic test results. This assessment is crucial for understanding potential health risks.
- Informed Decision-Making: Knowing your genetic risks allows you to make informed choices about genetic testing and reproductive options. This empowers you to take control of your health and family planning.
- Explaining Test Results: We interpret your genetic test results and explain their implications. This helps you understand what the results mean for you and your family.
- Emotional Support: We offer emotional support and coping strategies. Understanding genetic risks can be challenging, and our counsellors are here to help you navigate these emotions.
- Personalised Healthcare Recommendations: Based on your genetic profile, we provide personalised healthcare recommendations. This ensures you receive care tailored to your specific needs.
We are excited to welcome Ms Ailidh Watson to our team as our genetic counselling specialist. Ailidh is a registered private genetic counsellor with a broad range of experience. She has specialist interests in prenatal care and patients with cleft lip and/or palate. Her qualifications include a BSc (Hons) in Genetics from the University of Glasgow and an MSc in Genomic Counselling from the University of Manchester, where she graduated with distinction.
Ailidh’s credentials also include the Skilled Helper Course and registrations with AHCS and HCPC. Her services at LPC include genetic counselling, carrier screening, NIPT counselling, and prenatal screening, including NIPT. Ailidh will be your go-to person for all things genetic counselling.
Final Thoughts
London Pregnancy Clinic’s genetic counselling services represent a comprehensive approach to reproductive health. These services combine advanced genetic testing with expert counselling tailored to individual needs. They empower couples with the knowledge to make informed reproductive choices aligned with their values and circumstances.
